for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Prevail Therapeutics Inc

PRVL.OQ

Latest Trade

22.93USD

Change

0.02(+0.09%)

Volume

128,149

Today's Range

22.85

 - 

23.03

52 Week Range

9.03

 - 

23.35

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
22.91
Open
22.95
Volume
128,149
3M AVG Volume
9.02
Today's High
23.03
Today's Low
22.85
52 Week High
23.35
52 Week Low
9.03
Shares Out (MIL)
34.25
Market Cap (MIL)
785.31
Forward P/E
-9.55
Dividend (Yield %)
--

Latest Developments

More

Prevail Therapeutics Must Pay Eli Lilly Termination Fee Of $30 Mln In Event That Deal Terminated By Eli Lilly

Prevail Therapeutics Announces First Patient Dosed In Phase 1/2 Proclaim Clinical Trial Evaluating PR006 For The Treatment Of Frontotemporal Dementia Patients With GRN Mutations

Prevail Therapeutics Expects To Initiate Enrollment In Phase 1/2 Proclaim Trial Of Pr006 In Q4 Of 2020

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Prevail Therapeutics Inc

Prevail Therapeutics Inc. is a gene therapy company. The Company is developing and commercializing adeno-associated virus (AAV)-based gene therapies for patients with neurodegenerative diseases. It is engaged in applying a precision medicine approach to neurodegeneration by studying its gene therapies in genetically defined patient populations. The Company’s lead program is PR001 for the treatment of Parkinson’s disease with gaucher disease mutation, and neuronopathic gaucher disease. The Company is focused on developing a broad pipeline of gene therapies for a range of neurodegenerative diseases, including PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies.

Industry

Biotechnology & Drugs

Contact Info

430 E 29th St Ste 940

NEW YORK, NY

10016-8367

United States

+1.917.3369310

https://www.prevailtherapeutics.com/

Executive Leadership

Francois E. Nader

Independent Chairman of the Board

Asa Abeliovich

President, Chief Executive Officer, Director

Brett I. Kaplan

Chief Financial Officer

Yong Dai

Chief Technology Officer

Kira Schwartz

General Counsel

Key Stats

2.78 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020(E)

0.0K
EPS (USD)

2019

-2.220

2020(E)

-2.401
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
6.98
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-49.17
Return on Equity (TTM)
-45.68

Latest News

Latest News

BRIEF-Prevail Therapeutics Reports Full Year 2019 Financial Results And Business Highlights

* PREVAIL THERAPEUTICS REPORTS FULL YEAR 2019 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

BRIEF-Prevail Therapeutics Provides Clinical Advancement Update On Pr001 For The Treatment Of Parkinson's Disease With GBA1 Mutations

* PREVAIL THERAPEUTICS PROVIDES CLINICAL ADVANCEMENT UPDATE ON PR001 FOR THE TREATMENT OF PARKINSON’S DISEASE WITH GBA1 MUTATIONS

BRIEF-Prevail Therapeutics Announces Investigational NDA Active For PR006

* PREVAIL THERAPEUTICS ANNOUNCES INVESTIGATIONAL NEW DRUG APPLICATION ACTIVE FOR PR006 FOR THE TREATMENT OF FRONTOTEMPORAL DEMENTIA WITH GRN MUTATION Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up